Primary cilia orchestrate the multi-organ network in metabolic dysfunction-associated steatohepatitis
Hepatology Forum · 2026 · 7 (4) · 393-406
DOI: 10.14744/hf.2026.00221 ↗Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly prevalent cause of chronic liver disease and a major driver of cirrhosis and hepatocellular carcinoma worldwide. Although its pathogenesis involves complex interactions among metabolic, inflammatory, and neuroendocrine processes across multiple organs, current therapeutic strategies remain largely liver-centric and fail to address this systemic complexity. Primary cilia (PC) are evolutionarily conserved microtubule-based organelles that function as cellular sensory hubs, integrating extracellular signals and coordinating metabolic and inflammatory pathways. Emerging evidence from studies of ciliopathies, obesity, and neurodegeneration suggests that ciliary dysfunction may contribute to metabolic disorders affecting multiple organ systems. Here, we synthesize current evidence to propose a cilia-centered conceptual framework for MASH pathogenesis. We outline a dual-axis model in which PCs coordinate a horizontal metabolic axis linking the liver, gut, and pancreas to regulate glucose and lipid homeostasis, and a vertical neuro-metabolic axis connecting the brain, gut, and liver to integrate neural and endocrine signaling. Within these networks, cilia-associated pathways, including mammalian target of rapamycin, Hedgehog, Wnt/β-catenin, Notch, and transforming growth factor beta signaling, modulate key processes underlying steatosis, inflammation, and fibrogenesis. Dysfunction of PCs in hypothalamic neurons, pancreatic β-cells, intestinal stromal cells, and hepatic stellate cells may collectively amplify metabolic imbalance and inflammatory signaling, thereby promoting MASH progression. Understanding the systemic regulatory role of PC provides a unifying perspective on the multi-organ nature of MASH and highlights cilia-associated pathways as potential targets for therapeutic intervention.
EUVIMED